Introduction
L-Acetyl-Carnitine HCl (also known as acidic L-Acetyl-Carnitine) is a key active in energy and neuro-metabolic nutraceuticals, supporting mitochondrial fatty-acid transport and cellular ATP production. It is widely used in metabolic health, sport nutrition, neuro-muscular support, and healthy aging.
However, relevant sensory and technological limitations affect compliance and formulation performance.
The proprietary and patented MATRIS® technology enables transformation into a stable, acceptable, formulation-ready ingredient.
Formulation challenges
- Strong taste and odor
- High hygroscopicity, impacting:
- formulation stability
- powder flowability during manufacturing
- Difficult high-dose solid formulations
- Reduced consumer compliance
IPS innovation: L-Acetyl-Carnitine MATRIS®
Produced by direct microencapsulation using patented MATRIS® technology, delivering:
- effective taste masking
- physicochemicalprotection
- improved industrial processability
- compatibility with metabolic actives, especially Alpha-Lipoic Acid
Scientific evidence and ALA synergy
Direct preclinical studies on advanced in vitro 3D models and human intestinal, gastric, and neuronal organoids showed:
- more gradual and modulated release
- improved epithelial interaction
- reducedgastric/intestinal impact
- improved tolerability
- greater effectiveness on the peripheral nervous system
These findings support the metabolic rationale of the L-Acetyl-Carnitine + ALA combination.
Conclusion
L-Acetyl-Carnitine MATRIS® delivers a stable, tolerable, formulation-ready nutraceutical ingredient.
The demonstrated synergy with Alpha-Lipoic Acid further confirms SURACTIVES® by IPS as a technology provider for high-performance nutraceutical design.
Note: This article is provided for informational purposes only and does not substitute professional medical advice.
